ITCI Relative Valuation
ITCI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ITCI is overvalued; if below, it's undervalued.
Historical Valuation
Intra-Cellular Therapies Inc (ITCI) is now in the Fair zone, suggesting that its current forward PS ratio of 14.76 is considered Fairly compared with the five-year average of -44.32. The fair price of Intra-Cellular Therapies Inc (ITCI) is between 103.19 to 210.32 according to relative valuation methord.
Relative Value
Fair Zone
103.19-210.32
Current Price：131.90
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
12.20
P/B
Median3y
8.84
Median5y
7.50
-0.52
FCF Yield
Median3y
-3.13
Median5y
-5.14
Competitors Valuation Multiple
The average P/S ratio for ITCI's competitors is 18.25, providing a benchmark for relative valuation. Intra-Cellular Therapies Inc Corp (ITCI) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 50.81%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Intra-Cellular Therapies Inc (ITCI) currently overvalued or undervalued?
What is Intra-Cellular Therapies Inc (ITCI) fair value?
How does ITCI's valuation metrics compare to the industry average?
What is the current P/B ratio for Intra-Cellular Therapies Inc (ITCI) as of Jul 19 2025?
What is the current FCF Yield for Intra-Cellular Therapies Inc (ITCI) as of Jul 19 2025?
What is the current Forward P/E ratio for Intra-Cellular Therapies Inc (ITCI) as of Jul 19 2025?